Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bristol-Myers Squibb Company is spearheading a Phase 3 clinical study titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-2).’ The study aims to assess the safety and efficacy of the drug combination KarXT + KarX-EC in addressing agitation in Alzheimer’s patients, a significant concern due to its impact on patient quality of life and caregiver burden.
The study will test the experimental drugs Xanomeline/Trospium Chloride Capsule and Xanomeline Enteric Capsule against a placebo. These drugs are designed to alleviate symptoms of agitation in Alzheimer’s patients, potentially offering a new therapeutic option.
This interventional study is randomized and employs a parallel assignment model. It uses a quadruple masking approach to ensure unbiased results, with the primary purpose being treatment.
The study is set to begin on July 18, 2025, with an estimated primary completion date yet to be announced. The study was first submitted on June 2, 2025, and last updated on June 24, 2025. These dates are crucial for investors tracking the progress and potential market entry of new treatments.
For investors, this study represents a potential breakthrough in Alzheimer’s treatment, which could positively influence Bristol-Myers Squibb’s stock performance. The success of this study could position the company favorably against competitors in the Alzheimer’s treatment market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.